Skip to main content

Table 1 Demographics and clinical characteristics of IIM patients

From: Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate

Pt. no. Age (y) Sex Diagnosis, clinical Diagnosis, ACR/EULAR criteria, IIM probability (%) Cancer (Y/N) Muscle weakness (Y/N) Muscle biopsy Skin manifestations Dysphagia (Y/N) Autoantibodies (MSA/MAA) Increased CK level (Y/N) PYP uptake FDG uptake
1 75.5 F IMNM Probable IIM (86%), subgroup PM (IMNM) N Y Inflammatory infiltrates None Y Anti-SRP Y + +
2 74.7 M CAM Definite IIM (100%), subgroup DM Y Y No inflammation or perifascicular atrophy Heliotrope rash, Gottron’s papules Y None Y + ++
3 40.1 F DM Definite IIM (100%), subgroup DM N Y No inflammation or perifascicular atrophya Heliotrope rash, Gottron’s papules Y None Y + +
4 70.0 F DM Definite IIM (100%), subgroup DM N Y Inflammatory infiltrates Heliotrope rash, Gottron’s papules Y, feeding tube None Y + +++
5 70.4 M IMNM Possible IIM (53%) N Y Necrosis None Y None Y + ++
6 76.7 F CAM Definite IIM (100%), subgroup DM Y Y Inflammatory infiltrates Heliotrope rash, Gottron’s papules N None N ++ +
7 79.6 F PM Probable IIM (86%), subgroup PM (IMNM) N Y Inflammatory infiltrates None Y, feeding tube Anti-Ro52 Y ++ +
8 21.3 F IMNM Probable IIM (62%), subgroup PM (IMNM) N Y Inflammatory infiltrates and necrosis None N Anti-HMGCR Y NA +
  1. MSA/MAA: myositis-specific autoantibody/myositis-associated autoantibody (anti-Mi-2, SRP, PL-7, PL-12, OJ, EJ, Jo1, PM-Scl75/100, Ro52, KU, not including anti-NXP2, TIF1γ, SAE1, MDA5, cN1A, HMGCR, except patient number 8)
  2. y years, Y yes, N no
  3. aElectron microscopy with undulating tubules